1855-P: Sustained Glycemic Outcomes with Reduction in Burden: MiniMed 780G System Outcomes Are Met and Sustained in Children over a Three-Year Period

Introduction and Objective: AID systems have shown promise in bridging the gap between achieving international glycemic targets and the burden associated with achieving such outcomes.1 This study presents the first real-world 3-year evaluation of the MiniMedTM 780G (MM780G) system in the global pediatric population, assessing long-term glycemic outcomes and user burden. Methods: Carelink™ Personal data from January 1, 2020 to October 31,2025 were extracted from global MM780G users aged ≤15 yrs with T1D, who had ≥10 days of sensor data before automation and in each of the 36 months post-AHCL initiation. Endpoints included glycemic metrics, system use and insulin delivery and were aggregated monthly. User burden was defined as the percentage of insulin delivered by the user versus automatically by the system. Results: Among 1,699 users, TIR and TITR increased and remained above ADA glycemic goals at 36 months (Figure). TBR<70 remained consistently low and the proportion of insulin delivered by the system increased. While the average grams of carbohydrates entered increased in growing children, the number of carb entries per day decreased. Time in automated mode remained consistently above 96%. Conclusion: Children using the MM780G system showed rapid and durable improvement in glycemic outcomes over 3 years. The increase in the percentage of insulin delivered by the system versus the user may indicate reduced user burden for children and caregivers. Disclosure J. Cardin: Employee; Current; Medtronic. M. Juachon: None. J.J. Shin: Employee; Current; Medtronic. R. Vigersky: Employee; Current; Medtronic. J. McVean: Employee; Current; Medtronic.